IDYA
Price
$37.03
Change
+$1.94 (+5.53%)
Updated
Jan 14 closing price
Capitalization
3.25B
75 days until earnings call
Intraday BUY SELL Signals
IMVT
Price
$27.35
Change
+$1.17 (+4.47%)
Updated
Jan 14 closing price
Capitalization
5.51B
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs IMVT

Header iconIDYA vs IMVT Comparison
Open Charts IDYA vs IMVTBanner chart's image
IDEAYA Biosciences
Price$37.03
Change+$1.94 (+5.53%)
Volume$1.55M
Capitalization3.25B
Immunovant
Price$27.35
Change+$1.17 (+4.47%)
Volume$1.81M
Capitalization5.51B
IDYA vs IMVT Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
IMVT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. IMVT commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and IMVT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (IDYA: $37.03 vs. IMVT: $27.35)
Brand notoriety: IDYA and IMVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 164% vs. IMVT: 107%
Market capitalization -- IDYA: $3.25B vs. IMVT: $5.51B
IDYA [@Biotechnology] is valued at $3.25B. IMVT’s [@Biotechnology] market capitalization is $5.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileIMVT’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • IMVT’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while IMVT’s TA Score has 4 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • IMVT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both IDYA and IMVT are a good buy in the short-term.

Price Growth

IDYA (@Biotechnology) experienced а -2.19% price change this week, while IMVT (@Biotechnology) price change was +2.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

IMVT is expected to report earnings on Feb 18, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMVT($5.51B) has a higher market cap than IDYA($3.25B). IMVT YTD gains are higher at: 7.592 vs. IDYA (7.116). IDYA has higher annual earnings (EBITDA): -204.84M vs. IMVT (-486.69M). IDYA has more cash in the bank: 787M vs. IMVT (522M). IMVT has less debt than IDYA: IMVT (98K) vs IDYA (27.2M). IDYA has higher revenues than IMVT: IDYA (215M) vs IMVT (0).
IDYAIMVTIDYA / IMVT
Capitalization3.25B5.51B59%
EBITDA-204.84M-486.69M42%
Gain YTD7.1167.59294%
P/E RatioN/AN/A-
Revenue215M0-
Total Cash787M522M151%
Total Debt27.2M98K27,755%
FUNDAMENTALS RATINGS
IDYA vs IMVT: Fundamental Ratings
IDYA
IMVT
OUTLOOK RATING
1..100
1777
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
49
Fair valued
PROFIT vs RISK RATING
1..100
60100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
3841
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (26) in the null industry is in the same range as IMVT (49). This means that IDYA’s stock grew similarly to IMVT’s over the last 12 months.

IDYA's Profit vs Risk Rating (60) in the null industry is somewhat better than the same rating for IMVT (100). This means that IDYA’s stock grew somewhat faster than IMVT’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as IMVT (99). This means that IDYA’s stock grew similarly to IMVT’s over the last 12 months.

IDYA's Price Growth Rating (38) in the null industry is in the same range as IMVT (41). This means that IDYA’s stock grew similarly to IMVT’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as IMVT (100). This means that IDYA’s stock grew similarly to IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAIMVT
RSI
ODDS (%)
Bearish Trend 3 days ago
61%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 1 day ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
62%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
IMVT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGLYX11.700.08
+0.69%
Brookfield Global Listed InfrastructureI
CMJAX44.810.07
+0.16%
Calvert US Mid Cap Core Rspnb Idx A
FSFWX76.750.04
+0.05%
American Funds SMALLCAP World 529-F-3
BARAX88.76-0.20
-0.22%
Baron Asset Retail
GSEUX68.47-0.52
-0.75%
Goldman Sachs US Equity Insights R6

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+5.53%
NUVL - IDYA
59%
Loosely correlated
+6.59%
XNCR - IDYA
58%
Loosely correlated
+3.66%
XENE - IDYA
57%
Loosely correlated
+3.02%
DYN - IDYA
55%
Loosely correlated
+2.41%
IMTX - IDYA
54%
Loosely correlated
+4.80%
More

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+4.47%
ROIV - IMVT
61%
Loosely correlated
+1.58%
IDYA - IMVT
52%
Loosely correlated
+5.53%
CLDX - IMVT
50%
Loosely correlated
+1.58%
XENE - IMVT
50%
Loosely correlated
+3.02%
NUVL - IMVT
50%
Loosely correlated
+6.59%
More